Global Organ Transplant Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Product Type (Organ Preservation Solutions, Transplant Diagnostics, Tissue Products, Others), By Organ Type (Heart, Intestine, Kidney, Liver, Lung, Pancreas), By End-Users (Hospitals, Transplant Centers, Others), And By Geography – Forecast From 2022 To 2027

  • Published : Apr 2022
  • Report Code : KSI061612957
  • Pages : 120

The global organ transplant market is projected to grow at a CAGR of 8.51% during the forecast period to reach US$33.631 billion by 2027, from US$18.987 billion in 2020.

A major element driving market expansion is the rising need for innovative tissue transplantation products and organ transplantation to treat organ failure. Organ failure can be caused by several reasons, including severe trauma, poor eating habits, excessive alcohol intake, poisoning, blood loss, drug misuse, and other acute disorders. Diabetes and high blood pressure, for example, are the most common causes of end-stage kidney disease, which requires a renal transplant or dialysis to keep a patient alive. The need for tissue and organ transplantation, particularly kidney, heart, liver, and lungs transplantation, is quite high worldwide. In 2019, around 122,913 people were waiting for organ transplants in the United States, according to the US Department of Health and Human Services.

The market is also being boosted by the launch of technologically improved products and an increase in the number of tissue banks. According to the US Department of Health and Human Services, 43,201 people in the US were waiting for kidney transplants in 2019, although only 23,401 kidney transplants were carried out. Furthermore, recipients are prescribed potent immunosuppressive medicines following transplantation surgery, increasing their susceptibility to infectious infections as their immune is reduced. Technological advancements in novel transplant products and methods by biotechnology and medical device companies and rising healthcare spending are expected to boost the market.

Another factor driving the market is an increase in the prevalence of acute diseases like diabetes and high blood pressure that lead to end-stage renal disease. According to the World Health Organization (WHO), the geriatric population will exceed 2 billion by 2050. Liver, lung and kidney failures, cardiovascular illnesses, and other conditions are becoming increasingly common as a result of the rising prevalence of chronic diseases. This is a significant factor driving organ care product demand. Cirrhosis is the eleventh largest cause of death globally, and liver cancer is the sixteenth leading cause of death, according to the European Association for the Study of Liver.

However, limitations, such as a scarcity of organ donors for transplantation and high costs, are projected to limit market expansion. The need for organ care is being hampered by the high expense of therapy. The lengthy clearance process for novel organ care products hinders the organ care market's growth. The market's expansion is being hampered by a scarcity of trained specialists in the organ care system. Transplanting a human organ is a very sophisticated surgery requiring outstanding abilities. Because there are so few surgeons in this field who can perform these types of procedures, the cost of this procedure is extremely high. This aspect can potentially stifle the expansion of the organ transplantation market significantly. Furthermore, the number of organ donors is insignificant compared to the number of persons who require such organs. Another key aspect that may stymie the expansion of the organ transplantation market is the rising incidence of organ failure.

Key Developments

In December 2021, Penn Medicine announced that it had received a seven-year, $14 million grant from the National Institutes of Health (NIH) to apply chimeric antigen receptor T-cell immunotherapies to identify and treat patients in need of kidney transplants. OrganOx Limited debuted its ground-breaking liver perfusion equipment in January 2019. It was also given the green light by the UK's National Institute for Health and Care Excellence.

By product type, the global organ transplant market can be segmented into organ preservation solutions, transplant diagnostics, tissue products, and others. The tissue products category is expected to dominate the market. The segment's growth is fueled by rising demand for transplant operations such as cochlear implants, orthopedic soft tissues, heart valves, and bone marrow.

By organ type, the global organ transplant market can be segmented into heart, intestine, kidney, liver, lung, and pancreas. Renal or kidney transplantation is the most prevalent type of organ transplantation worldwide. Although various treatments for end-stage renal disease, such as dialysis, are available, kidney transplantation is widely regarded as the best option.

By end-users, the global organ transplant market can be segmented into transplant centers, hospitals, and others. The hospital's category accounted for the greatest proportion owing to the significant number of organ and tissue transplant procedures performed at hospitals. However, due to the rising demand for healthcare facilities that cater to patients' unmet requirements and government programs encouraging organ donation, the transplant centers category is likely to increase over the projection period.

By geography, the global organ transplant market can be segmented into the Asia Pacific, North America, the Middle East and Africa, South America, and Europe. Over the projected period, the Asia Pacific region is expected to grow at the highest rate. The developing medical tourism in Asia Pacific countries such as India, the growing geriatric population in various nations, and the rising prevalence of congenital hydrocephalus in China are all factors driving revenue growth in this regional market.

COVID-19 Insights

Access to solid organ transplantation has been hampered by the COVID-19 epidemic. During the epidemic, the number of transplants performed decreased globally. The most afflicted organ transplants were kidneys, followed by the lungs, liver, and heart. COVID-19 had a global impact on transplantation, with a 31% decline in solid organ transplants conducted during the first pandemic wave compared to the previous year. Approximately 48,000 years of patient life were lost as a result of this deterioration.

Global Organ Transplant Market Scope:

Report Metric Details
 Market size value in 2020  US$18.987 billion
 Market size value in 2027  US$33.631 billion
 Growth Rate  CAGR of 8.51% from 2020 to 2027
 Base year  2020
 Forecast period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments covered  Product Type, Organ Type, End-Users, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered OrganOx Limited, GlaxoSmithKline Plc., Pfizer, Organ Assist B.V., Paragonix Technologies Inc., Novartis AG, Preservation Solution Inc., Water Medical System LLC, Sanofi S.A, XVIVO Perfusion AB, Bridge to Life Ltd.
 Customization scope  Free report customization with purchase


Key Market Segments

  • By Product Type
    • Organ preservation solutions
    • Transplant diagnostics
    • Tissue products
    • Others
  • By Organ Type
    • Heart
    • Intestine
    • Kidney
    • Liver
    • Lung
    • Pancreas
  • By End-Users
    • Hospitals
    • Transplant Centers
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Taiwan
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the organ transplant market size by 2027?
A1. The global organ transplant market is projected to reach a total market size of US$33.631 billion by 2027.

Q2. What is the size of the global organ transplant market?
A2. Organ Transplant Market was valued at US$18.987 billion in 2020.  

Q3. What are the growth prospects for the organ transplant market?
A3. The organ transplant market is projected to grow at a CAGR of 8.51% over the forecast period. 

Q4. What factors are anticipated to drive the organ transplant market growth?
A4. A major element driving organ transplant market expansion is the rising need for innovative tissue transplantation products and organ transplantation for the treatment of organ failure.

Q5. Which region holds the largest market share in the organ transplant market?
A5. Over the projected period, the Asia Pacific region is expected to hold the largest share in the organ transplant market.

1.1. Market Definition
1.2. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The Threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis

5.1. Introduction
5.2. Organ preservation solutions
5.3. Transplant diagnostics
5.4. Tissue products
5.5. Others

6.1. Introduction
6.2. Heart 
6.3. Intestine 
6.4. Kidney
6.5. Liver
6.6. Lung 
6.7. Pancreas

7.1. Introduction
7.2. Hospitals
7.3. Transplant Centers
7.4. Others

8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom 
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. Israel
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. Japan
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Taiwan 
8.6.8. Others

9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrative
9.3. Mergers, Acquisition, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix

10.1. OrganOx Limited
10.2. GlaxoSmithKline Plc.
10.3. Pfizer
10.4. Organ Assist B.V.
10.5. Paragonix Technologies Inc. 
10.6. Novartis AG
10.7. Preservation Solution Inc.
10.8. Water Medical System LLC
10.9. Sanofi S.A
10.10. XVIVO Perfusion AB
10.11. Bridge to Life Ltd.

OrganOx Limited

GlaxoSmithKline Plc.


Organ Assist B.V.

Paragonix Technologies Inc.

Novartis AG

Preservation Solution Inc.

Water Medical System LLC

Sanofi S.A

XVIVO Perfusion AB

Bridge to Life Ltd.